In a cautious investment climate, dental 3D printing continues to draw high-profile capital. Lei Jun's Shunwei Capital and Masayoshi Son's SoftBank Vision Fund have both backed the sector, reflecting strong long-term conviction in its growth potential, policy tailwinds, technological disruption, and the structural advantages of the upstream dental supply chain.
Why the Upstream Dental Segment Remains Hot
Strong demand fundamentals Rising disposable incomes and the "beauty economy" are driving greater attention to dental health and aesthetics. China's oral healthcare service market reached approximately RMB 150.7 billion in 2021 and was projected at RMB 173.9 billion in 2022. By 2026 it is expected to hit RMB 318.2 billion, implying a compound annual growth rate of about 15.6% from 2022 to 2026.
Capital prefers upstream Upstream players (equipment and materials manufacturers) enjoy high barriers to entry, strong technology moats, and global scalability:
New products typically require 2–5 years of clinical trials and regulatory approval.
Solutions involve multidisciplinary integration of materials science, optics, software, and clinical workflows.
High standardization enables international expansion.
Clear competitive advantages
Superior profitability: Upstream dental companies typically achieve gross margins of 40–80%, significantly higher than midstream (10–30%) and downstream service providers (20–50%). Downstream margins are compressed by doctor costs and patient acquisition expenses; midstream players often lack proprietary technology and face e-commerce pressure.
Higher market concentration: Elevated entry barriers create a more concentrated landscape and larger addressable markets per leading company. China's oral care penetration rate was only around 24% in 2020 versus roughly 70% in the United States, leaving substantial room for upstream suppliers to capture growing demand.
Why 3D Printing Has Become Capital's New Favorite
Digitalization raises the ceiling of clinical care The digital maturity of upstream products directly determines the quality and efficiency of downstream clinical services. 3D printing enables truly customized, precise solutions that improve treatment outcomes and patient experience. Chinese companies have made notable progress in dental 3D printing and are increasingly challenging established international players.
Attractive market size According to Markets and Markets, the global dental 3D printing market was valued at USD 3.2 billion in 2022 and is projected to reach USD 7.9 billion by 2027, representing a CAGR of 20.2%.
Policy support China's National Healthy Oral Action Plan (2019–2025) explicitly calls for accelerating the localization of high-end oral devices and materials, including implants and biological 3D printing technologies.
Technology-driven industry upgrade 3D printing's strength in mass customization perfectly matches dental needs. Metal 3D printing is used for crowns and frameworks; light-curing (DLP/LCD) technology is widely applied for models, surgical guides, and clear aligner molds. Production speed can increase by up to 100 times while costs drop significantly, accelerating the shift toward fully digital dentistry.
Specific Investments by Lei Jun and Masayoshi Son
Lei Jun / Shunwei Capital: In April 2021, Shunwei completed a tens-of-millions RMB C+ round investment in Xunshi Technology (LuxCreo). The company focuses on 3D printing equipment and materials, building a competitive moat across hardware, consumables, workflow software, design services, and AI design. It has reported nearly 80% compound revenue growth, with R&D staff accounting for about 35% of the workforce. Its 3D printers have an installed base of over 10,000 units in the U.S., capturing more than 50% share of the existing market.
Masayoshi Son / SoftBank Vision Fund: In October 2022, SoftBank Vision Fund II led an over USD 100 million D-round investment in the same company. SoftBank has a long track record in healthcare; Vision Fund I's second-highest returning investment was Uber, yet certain healthcare bets generated even higher absolute returns. By mid-2021, Vision Fund II had already invested in more than a dozen healthcare companies. The combination of market potential, policy support, and Xunshi's technical and commercial traction made the sector an attractive target.
Remaining Industry Challenges
Despite the optimism, several hurdles persist:
High equipment costs: High-resolution dental 3D printers typically range from USD 40,000–100,000, limiting adoption among smaller laboratories.
Elevated operating costs: Many 3D-printed procedures are not fully covered by insurance; specialized software and dental resins remain more expensive than conventional materials.
Talent shortage: Skilled professionals who understand both 3D printing technology and clinical dentistry remain scarce. Training programs lag behind rapid technological progress.
Intense price competition: Aggressive pricing and even free equipment placement by some vendors have compressed margins below the true value of the technology.
Outlook and Opportunity
The dual endorsement by Lei Jun and Masayoshi Son underscores the structural attractiveness of dental 3D printing. For clinics and laboratories looking to capture this growth, choosing reliable, high-precision, open-system solutions is critical.
At Aident Technology, we provide a complete digital dentistry ecosystem - high-accuracy intraoral and lab scanners, the Ai-C60 chairside and Ai220 lab 3D printers, and a full range of biocompatible dental resins. Our solutions are designed to deliver the speed, precision, and cost-effectiveness that modern digital workflows demand.
Explore how Aident can help your practice or laboratory participate in the next wave of dental digitalization: https://www.aident3d.com/dental-3d-printer/
Contact us for product details, ROI analysis, or partnership opportunities.
